JST Distribution LLC alleged that eLine LP marketed drug-spiked competition to its “all-natural” sexual enhancement supplement, prompting eLine to remove the suspect products that a third-party was selling on its website, which led to JST agreeing to dismiss its litigation on Aug. 17. JST’s complaint filed April 28 in federal court in Los Angeles alleged violations of federal and state advertising laws and that brands FDA identified as products marketed as supplements but spiked with erectile dysfunction drug sildenafil were available through eLine on a website branded “Romantix.” The Spring, Texas, firm argued “eLine’s representations regarding these products are false and misleading,” notably the “Enhancement Products” labeled as supplements despite “unlawfully containing hidden drug ingredients.” However, eLine responded that it did not control Romantix’ inventory and while it “admits that some of the products identified in” JST’s complaint were offered on the Romantix website, no sales were recorded since before April 9 and the products were removed April 14. Also, the San Francisco online and conventional retailer said it “reasonably relies upon product manufacturers to provide information on their products,” and it “denies that it knowingly offered for sale any mislabeled product or any product containing sildenafil or any other chemical in sufficient amount to require a prescription for sale.”
JST, which noted in its complaint that FDA has reported “a growing trend in the supplement industry of mislabeling ‘dietary...







